Veritas In Silico (TSE:130A) Research & Development: 円240.83 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:130A Veritas In Silico Inc TSE:130A
28 GF Score
Price 円433.00
GF Value 円266.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Veritas In Silico Research & Development?

Veritas In Silico TSE:130A -2.26% 28 Research & Development is 円240.83 Mil as of Jun. 2026. GuruFocus rates TSE:130A with a GF Score™ of 28/100 and a GF Value™ of 円266.78 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Veritas In Silico's Research & Development for the three months ended in Jun. 2026 was 円0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was 円240.83 Mil.

Veritas In Silico  (TSE:130A) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Veritas In Silico Research & Development Related Terms

Veritas In Silico Research & Development Historical Data

* Premium members only.

The historical data trend for Veritas In Silico's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veritas In Silico Research & Development Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
129.10 148.33 136.55 172.48 215.62

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.30 59.58 61.91 67.03 0.00
TSE:130A
28GF Score
Veritas In Silico Inc TSE:130A
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veritas In Silico Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円240.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円240.83 Mil mean?
Veritas In Silico (TSE:130A) has a Research & Development of 円240.83 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Veritas In Silico and its competitors.
Is Veritas In Silico's Research & Development too high?
Veritas In Silico's current Research & Development is 円240.83 Mil. Overall, Veritas In Silico has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Research & Development compare to VRTX and REGN?
Veritas In Silico's Research & Development of 円240.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Veritas In Silico and its competitors. Veritas In Silico's current Research & Development is 円240.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Based on GuruFocus' analysis, Veritas In Silico (TSE:130A) is currently considered Significantly Overvalued. The stock's GF Value™ is 円266.78, compared to a current price of 円433.00 — trading 62.3% above its estimated fair value. The current Research & Development is 円240.83 Mil. Veritas In Silico's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Research & Development is 円240.83 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veritas In Silico (TSE:130A) Overvalued in 2026?

Based on GuruFocus' analysis, Veritas In Silico stock appears to be overvalued. The current stock price of 円433.00 is trading 62.3% above its estimated GF Value™ of 円266.78. GuruFocus considers Veritas In Silico to be Significantly Overvalued.

Key valuation signals for TSE:130A:

  • Research & Development: 円240.83 Mil
  • GF Value™: 円266.78 vs. price of 円433.00 (62.3% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TSE:130A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Veritas In Silico Business Description

Address 1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
28GF Score

Get the complete analysis for TSE:130A

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円433.00
Price
円266.78
GF Value